Literature DB >> 16547278

Severe disease, unaltered leukocyte migration, and reduced IFN-gamma production in CXCR3-/- mice with experimental autoimmune encephalomyelitis.

Liping Liu1, Deren Huang, Masaru Matsui, Toby T He, Taofang Hu, Julie Demartino, Bao Lu, Craig Gerard, Richard M Ransohoff.   

Abstract

Experimental autoimmune encephalomyelitis (EAE) is a CD4(+) Th1 T cell-mediated disease of the CNS, used to study certain aspects of multiple sclerosis. CXCR3, the receptor for CXCL10, CXCL9, and CXCL11, is preferentially expressed on activated Th1 T cells and has been proposed to govern the migration of lymphocytes into the inflamed CNS during multiple sclerosis and EAE. Unexpectedly, CXCL10-deficient mice were susceptible to EAE, leaving uncertain what the role of CXCR3 and its ligands might play in this disease model. In this study, we report that CXCR3(-/-) mice exhibit exaggerated severity of EAE compared with wild-type (CXCR3(+/+)) littermate mice. Surprisingly, there were neither quantitative nor qualitative differences in CNS-infiltrating leukocytes between CXCR3(+/+) and CXCR3(-/-) mice with EAE. Despite these equivalent inflammatory infiltrates, CNS tissues from CXCR3(-/-) mice with EAE showed worsened blood-brain barrier disruption and more von Willebrand factor-immunoreactive vessels within inflamed spinal cords, as compared with CXCR3(+/+) mice. Spinal cords of CXCR3(-/-) mice with EAE demonstrated decreased levels of IFN-gamma, associated with reduced inducible NO synthase immunoreactivity, and lymph node T cells from CXCR3(-/-) mice primed with MOG(35-55) secreted less IFN-gamma in Ag-driven recall responses than cells from CXCR3(+/+) animals. CXCR3(-/-) lymph node T cells also showed enhanced Ag-driven proliferation, which was reduced by addition of IFN-gamma. Taken with prior findings, our data show that CXCL10 is the most relevant ligand for CXCR3 in EAE. CXCR3 does not govern leukocyte trafficking in EAE but modulates T cell IFN-gamma production and downstream events that affect disease severity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16547278     DOI: 10.4049/jimmunol.176.7.4399

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  54 in total

Review 1.  G protein-coupled receptors as therapeutic targets for multiple sclerosis.

Authors:  Changsheng Du; Xin Xie
Journal:  Cell Res       Date:  2012-06-05       Impact factor: 25.617

2.  Adjuvant immunotherapy of experimental autoimmune encephalomyelitis: immature myeloid cells expressing CXCL10 and CXCL16 attract CXCR3+CXCR6+ and myelin-specific T cells to the draining lymph nodes rather than the central nervous system.

Authors:  Richard A O'Connor; Xujian Li; Seth Blumerman; Stephen M Anderton; Randolph J Noelle; Dyana K Dalton
Journal:  J Immunol       Date:  2012-01-27       Impact factor: 5.422

3.  CCR5 expression on monocytes and T cells: modulation by transmigration across the blood-brain barrier in vitro.

Authors:  Eroboghene E Ubogu; Melissa K Callahan; Barbara H Tucky; Richard M Ransohoff
Journal:  Cell Immunol       Date:  2007-01-25       Impact factor: 4.868

Review 4.  Th17 cells: effector T cells with inflammatory properties.

Authors:  Thomas Korn; Mohamed Oukka; Vijay Kuchroo; Estelle Bettelli
Journal:  Semin Immunol       Date:  2007-11-26       Impact factor: 11.130

5.  Neuroprotection and remyelination after autoimmune demyelination in mice that inducibly overexpress CXCL1.

Authors:  Kakuri M Omari; Sarah E Lutz; Laura Santambrogio; Sergio A Lira; Cedric S Raine
Journal:  Am J Pathol       Date:  2008-12-18       Impact factor: 4.307

6.  C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE.

Authors:  Andrea Reboldi; Caroline Coisne; Dirk Baumjohann; Federica Benvenuto; Denise Bottinelli; Sergio Lira; Antonio Uccelli; Antonio Lanzavecchia; Britta Engelhardt; Federica Sallusto
Journal:  Nat Immunol       Date:  2009-03-22       Impact factor: 25.606

7.  Naturally presented peptides on major histocompatibility complex I and II molecules eluted from central nervous system of multiple sclerosis patients.

Authors:  Nicolas Fissolo; Sabrina Haag; Katrien L de Graaf; Oliver Drews; Stefan Stevanovic; Hans Georg Rammensee; Robert Weissert
Journal:  Mol Cell Proteomics       Date:  2009-06-16       Impact factor: 5.911

8.  Enhancement of blood-brain barrier permeability and reduction of tight junction protein expression are modulated by chemokines/cytokines induced by rabies virus infection.

Authors:  Qingqing Chai; Wen Q He; Ming Zhou; Huijun Lu; Zhen F Fu
Journal:  J Virol       Date:  2014-02-12       Impact factor: 5.103

9.  The chemokine receptor antagonist, TAK-779, decreased experimental autoimmune encephalomyelitis by reducing inflammatory cell migration into the central nervous system, without affecting T cell function.

Authors:  Jia Ni; Yi-Na Zhu; Xiang-Gen Zhong; Yu Ding; Li-Fei Hou; Xian-Kun Tong; Wei Tang; Shiro Ono; Yi-Fu Yang; Jian-Ping Zuo
Journal:  Br J Pharmacol       Date:  2009-12       Impact factor: 8.739

Review 10.  Chemokines and chemokine receptors: standing at the crossroads of immunobiology and neurobiology.

Authors:  Richard M Ransohoff
Journal:  Immunity       Date:  2009-11-20       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.